Sponsored · Video

Exicure’s CEO describes unique SNA™ technology now in clinical trials

Dr. David Giljohann, CEO of Exicure, outlines the company’s unique spherical nucleic acid (SNA™) technology and how this three-dimensional arrangement of nucleic acid will solve the delivery challenge to get into cells and tissues. The biotech company is using digital drug design to use DNA and RNA sequences to create medicines that go after the underlying causes of genetic disease. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology

Trending on Xconomy